Loading…
Based on limited metadata, the FDA issued a warning letter to Longood Medicine (Beijing) Co Ltd, a Chinese pharmaceutical or medical products company, on August 27, 2018. While the specific violations cannot be detailed due to unavailable subject line information, the letter indicates regulatory concerns with the company's operations or products. The exact nature of the violations and the specific FDA office involved remain unclear from the available metadata, though the product category is noted as "Other," suggesting the warning may relate to a non-traditional pharmaceutical or medical device category.